Skip to main content
. 2018 Jan 1;9(3):594–603. doi: 10.7150/jca.20461

Figure 2.

Figure 2

Kaplan-Meier estimates of the survival outcomes in nasopharyngeal carcinoma patients treated with nimotuzumab and without nimotuzumab.